CPT 81419: Genomic Sequence Analysis Panel for Epilepsy
Commercial payers pay $2356 on average nationally for this procedure.
CPT code 81419 describes a laboratory genomic sequence analysis panel where the laboratory performs technical sequencing on a specimen (typically blood) to evaluate the genetic sequences of at least 24 specified genes; the test is used to help diagnose or indicate genetic predisposition to epilepsy. Service type: genetic/genomic diagnostic testing. Typical site of service: clinical laboratory or molecular diagnostics laboratory, specimen collected from outpatient or inpatient settings.
For related coverage guidance, see recent payer policy updates: Oral Cancer Screening and Testing, RTM Testing for Alpha-1 Antitrypsin Deficiency, Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policy.
Customize your policy alerts
Sign up for cpt 81419 policy alerts
Get alerted when payer policies referencing 81419 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial pricing for CPT 81419 centers on BUCA as the average commercial benchmark at $2,356.50, with individual national payers showing notable dispersion. Blue Cross Blue Shield posts the widest interquartile spread (P75–P25 = $1,280.50), reflecting more variability among higher-end contracts, while Aetna is the tightest (P75–P25 = $776.50). UnitedHealth Group and Cigna show intermediate spreads of $1,469.20 and $1,729.40 respectively, indicating broader variability across those networks.
Across payers the median and mean relationships highlight differing skew: Blue Cross Blue Shield and UnitedHealth Group have mean rates above their medians, suggesting higher outliers lift averages, whereas Aetna’s median exceeds its mean slightly. BUCA’s mean at $2,356.50 sits among the higher commercial means, serving as a useful central benchmark for national commercial pricing comparisons.